CONMED Corporation $CNMD Shares Acquired by Pacer Advisors Inc.

Pacer Advisors Inc. increased its holdings in shares of CONMED Corporation (NYSE:CNMD) by 11.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 158,773 shares of the company’s stock after buying an additional 15,765 shares during the period. Pacer Advisors Inc. owned about 0.53% of CONMED worth $5,614,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in CONMED by 2.0% during the fourth quarter. Vanguard Group Inc. now owns 3,684,439 shares of the company’s stock worth $149,588,000 after acquiring an additional 73,533 shares during the period. Dimensional Fund Advisors LP grew its position in shares of CONMED by 6.1% in the first quarter. Dimensional Fund Advisors LP now owns 1,392,920 shares of the company’s stock valued at $49,250,000 after purchasing an additional 80,116 shares during the period. Wasatch Advisors LP acquired a new stake in shares of CONMED in the third quarter valued at about $47,026,000. Cooke & Bieler LP increased its stake in shares of CONMED by 23.2% during the fourth quarter. Cooke & Bieler LP now owns 867,817 shares of the company’s stock worth $35,233,000 after purchasing an additional 163,494 shares in the last quarter. Finally, Deerfield Management Company L.P. increased its stake in shares of CONMED by 8.6% during the third quarter. Deerfield Management Company L.P. now owns 760,196 shares of the company’s stock worth $35,752,000 after purchasing an additional 59,925 shares in the last quarter.

Analyst Upgrades and Downgrades

CNMD has been the topic of a number of research reports. JPMorgan Chase & Co. decreased their price target on shares of CONMED from $43.00 to $40.00 and set a “neutral” rating on the stock in a research note on Thursday, April 30th. Piper Sandler reiterated a “neutral” rating and set a $45.00 price objective (up from $39.00) on shares of CONMED in a research note on Thursday, July 30th. Zacks Research lowered CONMED from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. BMO Capital Markets initiated coverage on CONMED in a report on Wednesday, July 8th. They set a “market perform” rating and a $36.00 target price for the company. Finally, Wells Fargo & Company raised their target price on CONMED from $39.00 to $46.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. Five research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $41.40.

CONMED Price Performance

Shares of NYSE CNMD opened at $49.42 on Thursday. The firm has a 50-day simple moving average of $38.12 and a 200-day simple moving average of $38.64. The company has a quick ratio of 0.69, a current ratio of 1.48 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $1.48 billion, a price-to-earnings ratio of 26.71, a price-to-earnings-growth ratio of 2.30 and a beta of 0.88. CONMED Corporation has a 52 week low of $31.44 and a 52 week high of $56.63.

CONMED (NYSE:CNMD) last posted its quarterly earnings results on Wednesday, July 29th. The company reported $1.38 earnings per share for the quarter, topping analysts’ consensus estimates of $1.11 by $0.27. CONMED had a net margin of 4.12% and a return on equity of 14.31%. The firm had revenue of $343.49 million for the quarter, compared to analyst estimates of $337.60 million. During the same period in the previous year, the business posted $1.15 earnings per share. CONMED’s quarterly revenue was up .3% on a year-over-year basis. CONMED has set its FY 2026 guidance at 4.480-4.600 EPS. On average, equities analysts predict that CONMED Corporation will post 4.54 earnings per share for the current fiscal year.

CONMED Profile

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.